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Role of 131I in the Treatment of Well
Differentiated Thyroid Cancer
DEREK T. WOODRUM, MD AND PAUL G. GAUGER, MD*
Division of Endocrine Surgery, University of Michigan Department of Surgery, Ann Arbor, Michigan
131I is an integral component in postsurgical management of well-differentiated
thyroid cancer (WDTC), which includes papillary and follicular types. 131I is used
postsurgically to either destroy remaining thyroid tissue (thyroid ablation) or to treat
recurrence and metastases (radioiodine therapy). 131I is no longer a routine diagnostic
modality, but it is widely used for remnant ablation after thyroidectomy for WDTC>
1 cm, under conditions of thyroxine withdrawal. It is generally—though not
unanimously—accepted that postsurgical radioiodine is the most powerful method
by which to lengthen disease-free survival. 131I cannot be used if the residual thyroid
remnant is large; many surgeons therefore perform near-total or total thyroidectomy
for all WDTC> 1 cm. Since 1997, radioiodine treatment has been performed in
outpatient settings, where side effects are common, but mild and transient. Secondary
screening is by physical exam, thyroglobulin measurements, and 131I diagnostic
whole-body scans. This is performed under conditions of thyrotropin stimulation,
which is accomplished either by thyroxine withdrawal or administration of recom-
binant human thyrotropin. While most cancers are well treated with radioiodine, some
advanced cancers may no longer take up radioiodine, rendering them resistant to
treatment. For these cancers, redifferentiation therapy and molecular target-specific
medicines hold future promise for improved treatment.
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INTRODUCTION
On the surface, the basic treatment principles of well
differentiated thyroid carcinoma (WDTC) seem clear and
well-established: initial management is surgical removal
of the thyroid gland and locoregional metastases, follow-
ed by postoperative ablation or therapy with radioiodine.
The next phase in care is one of periodic secondary scre-
ening, and local or distant recurrences are generally
treated with surgery or radioiodine as appropriate. Of
course tumor biology is generally favorable, but this
treatment strategy is a simple formula that appears to
work. Patients with WDTC have survival estimates that
exceed most other malignancies. In the National Cancer
Data Base (NCDB) study of greater than 53,000 thyroid
cancers reported between 1985 and 1995, the 10-year
survival for WDTC was 85% (follicular cancers) and
93% (papillary cancers) [1]. Furthermore, it has been
suggested that radioiodine therapy is very important in
the treatment of WDTC. A large retrospective study of
patients with WDTC showed that treatment with radio-
iodine (after surgery) was the most powerful prognostic
indicator for increased disease-free survival [2]. Despite
these findings, extensive practice pattern variations exist
with regard to patient selection (i.e., threshold for
treatment), radioiodine dose, follow-up intervals, method
of TSH stimulation, and the treatment of recurrences.
There are no randomized, prospective trials in this body of
literature, and the clinical practice pattern guidelines that
have evolved are largely based on data from retrospective
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case series. As such, most guidelines represent Level 2
evidence—that is, consensus among experts without
major disagreement. Some areas of treatment (e.g.,
thyroxine withdrawal vs. recombinant human thyrotro-
pin) generate major disagreement among experts and are
regarded as Level 3 evidence.
In this chapter, we address the utility of 131I in the
diagnosis and management of both primary and recurrent
well differentiated (papillary and follicular) thyroid
carcinoma. The role of recombinant human thyroid-
stimulating hormone (rhTSH; ThyrogenTM) is discussed
as well, and we include a proposed algorithm for secon-
dary screening and follow-up after initial treatment for
thyroid carcinoma.
BACKGROUND
Radioiodine is used in the post-surgical treatment of
WDTC for either thyroid ablation or therapy. Thyroid
ablation refers to the use of radioiodine to destroy the
remaining normal thyroid tissue after less-than-total
thyroidectomy (intended or otherwise), while therapy
refers to the use of radioiodine to treat residual or
recurrent thyroid cancer at the thyroid bed or more distant
metastatic locations [3]. The terms can become confus-
ing, however, especially when a total or near-total thyro-
idectomy is performed for WDTC. Although a dose of
radioiodine may be given with the intent to clear the
thyroid bed of remaining normal thyroid tissue (ablation),
it cannot be assumed that the remaining tissue was free of
cancer deposits (for which the treatment would be
radioiodine therapy). Once accumulated within the cells,
131I undergoes beta decay releasing high energy electrons
for a short distance into the surrounding tissues. This
cytotoxicity is quite focused and generally thought to
effect tissues only within a 2 mm radius. Gamma rays are
also released which allow for the radioisotope’s use in
scanning procedures. Of course, the cytotoxic decay only
affects tissue which concentrates radioiodine. Problema-
tically, dedifferentiated thyroid cancers can lose their
ability to concentrate iodine, and therefore may receive
substantial radiation only if closely neighbored by normal
thyroid tissue. For similar reasons, large amounts of tis-
sue (e.g., a large thyroid remnant) are difficult to destroy,
which may influence the initial surgical approach.
PRIMARY CANCER
Diagnosis
Historically, thyroid scintigraphy using 131I was used
routinely in the workup of a thyroid nodule. Diagnostic
and treatment algorithms were generated based on the
various perturbations of history, physical exam, and
whether the thyroid nodule had lost the ability to con-
centrate the radioactive isotope. The thyroid scan has
been used far less over the past decade, commensurate
with the widespread use and documented utility of fine
needle aspiration for diagnosis. For diagnosis of a prim-
ary cancer, the thyroid scan is not routinely used.
Treatment
Radioiodine may be used in two ways after thyroi-
dectomy: low doses are used to demonstrate remaining
thyroid tissue or metastatic disease as part of a radio-
iodine thyroid scan, while higher doses are used for
ablation or therapy. The timing of the initial postoperative
scan is dictated by the physiology of T4. In order for
remnant tissue to take up radioiodine, it must be stim-
ulated by elevated levels of TSH. Although no precise
threshold has been established, a general consensus is
held that the TSH should be at least 30 mIU/ml. The TSH
rise is generally achieved by thyroxine withdrawal,
although recombinant human TSH is available (see
below). Circulating T4 (either secreted from the thyroid
gland or provided by exogenous supplementation) delays
the rise in TSH. The half life of thyroxine is approxi-
mately 7 days, so TSH values are significantly elevated
4–5 weeks after total thyroidectomy or withdrawal from
thyroxine treatment. In order to minimize the duration of
hypothyroid symptoms, patients can be managed on T3
(CytomelTM) for the first 4 postoperative weeks. Due to
the much shorter half-life of T3 (8–12 hr), it is held for
2 weeks prior to scanning [4–6].
Patient selection. Radioiodine therapy is well suited
to WDTC because most tumor cells have the ability to
concentrate radioiodine. Additionally, many studies have
shown a decreased rate of recurrence and increased
disease-specific and overall survival when 131I is used.
Mazzaferri [7] reported in 1997 a three-fold decrease in
the incidence of distant metastatic disease and local
tumor recurrence in tumors treated with radioiodine. In
another study, the risk of cancer death was decreased by
half (from 16% to 8%) when radioiodine was used after
surgery compared to hormone replacement or external
radiation alone [8]. Many treatment centers, retrospective
studies, and individual clinicians agree that radioiodine is
beneficial and well tolerated, but certainly this is not a
unanimous conclusion. For instance, Hay et al. [9] re-
viewed the outcomes for nearly 2,500 patients with
papillary thyroid carcinoma patients treated over six
decades at a single institution. In this long-term retro-
spective review, the investigators show that the utilization
of postoperative remnant ablation has greatly increased
over the past several decades. Nevertheless, they report
stable recurrence and cause-specific mortality rates even
in the face of increased utilization of radioiodine therapy
[9]. They conclude that routine radioiodine treatment for
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all patients is unjustified, particularly for those with low-
risk cancers.
As mentioned previously, there are no prospective,
randomized trials with subgroup analysis to shed light
on the dilemma of which patients should receive post-
operative radioiodine. The argument is further com-
plicated by the fact that more than five staging and
prognostic systems are currently used, and comparisons
across studies can be difficult. For instance, Cady and
Rossi at the Lahey Clinic reported a reluctance to treat
low risk patients (men under 41 and women under 51)
without metastatic disease at original operation [10], but
Samaan [2] has suggested a more universal approach to
remnant ablation, as has Beierwaltes [11].
It is safe to summarize that postoperative radioiodine is
commonly used, even for lower-risk cancers, and thyroid
remnant ablation is generally accepted as part of the
postoperative treatment of patients who have undergone
total or near-total thyroid excision for WDTC. It is also
widely recognized that this approach may not be the final
answer, and it is not clear that using postoperative
radioiodine to ‘‘clear’’ a whole-body scan will impact the
patient’s recurrence or survival. The future of WDTC
treatment will likely involve an approach where patients
are selected for postoperative radioiodine therapy based
on individual risk assessment. Such assessment tools will
need to be prospectively validated in a randomized
fashion to offer the greatest help in selecting patients for
radioiodine.
Several situations exist wherein it is generally agreed
that 131I is not necessary (or beneficial). If the cancer is
non-differentiated and does not concentrate radioiodine,
ablative or therapeutic efforts will be futile. Lesions
smaller than 1 cm without evidence of metastatic disease
are not treated with radioiodine because of their ex-
ceptionally low potential for local or distant recurrence.
Finally, if only a lobectomy is performed, the radioiodine
ablation is only possible 25% of the time (due to the
volume of residual tissue) [12].
Relationship of surgical approach to postoperative
radioiodine. The choice of thyroid operation for
WDTC (i.e., total vs. subtotal vs. lobectomy) is not the
focus of this chapter, but it is not always obvious that the
extent of the resection actually affects the overall prog-
nosis. However, thyroid surgery for WDTC is relatively
unique among solid organ cancers in that the extent of
resection (total vs. less-than-total thyroidectomy) directly
affects the postoperative treatment options. As stated
previously, radioiodine therapy is unlikely to be bene-
ficial (or even possible) and is not used if a less-than-total
thyroidectomy is performed. Surgery (typically total
thyroidectomy) and postoperative radioiodine therapy
[13] are generally agreed upon as standard treatment for
those cancers 1 cm or greater. The theory behind this
practice pattern is that residual microscopic disease (not
removed by the original operation) would be eliminated
with radioiodine treatment. As in the previous section on
patient selection, this contention is generally accepted,
but certainly not universal. For instance, the Mayo Clinic
group has reported no difference in the frequency of local
recurrence in those patients that underwent total thyro-
idectomy vs. bilateral subtotal thyroidectomy, suggesting
the theory that postoperative 131I treats ‘‘residual micro-
scopic disease’’ may not be correct [14]. Additionally, the
Mayo team showed that survival was not improved by
total thyroidectomy (compared to bilateral subtotal
thyroidectomy) in either minimal or higher risk patients
with papillary carcinoma.
Indications and benefits of therapeutic radioiodine.
Freitas has described the generally accepted indi-
cations for 131I treatment: inoperable primary tumor,
postoperative residual tumor in the neck, capsular in-
vasion, local recurrence, and the presence of distant,
cervical, or mediastinal metastatic disease [15]. Propo-
nents of 131I advocate that all patients who meet the
indications for total thyroidectomy should undergo
postoperative radioiodine therapy because it should not
be assumed that residual thyroid tissue in the neck is
tumor-free. Importantly, between 24% and 50% of
well differentiated thyroid cancers will be multifocal,
multicentric, or microscopic [8,16]. In these settings,
postoperative remnant thyroid ablation after total thyro-
idectomy serves to destroy remaining thyroid tissue that
may harbor occult microscopic carcinoma. There are
additional compelling reasons to provide postoperative
radioiodine ablation. In short, it is easier to manage and
follow the patient without remaining thyroid tissue.
Without competing normal tissue, visualization of local
or distant recurrences on follow-up 131I scanning is pos-
sible. If large amounts of thyroid tissue remained after
the initial operation, the bright emission of 131I from the
residual thyroid will obscure any small areas of local
recurrence. Additionally, remaining thyroid tissue will
cause TSH suppression, which can decrease the uptake of
131I during postoperative imaging [11]. Finally, thyroglo-
bulin (TG) measurements are the most specific tests for
recurrent cancer when no normal thyroid tissue is present,
no TG antibodies (TG-Ab) are present, and when TG
level is measured during a period of hypothyroidism—
none of which are feasible when a remnant remains [17].
It follows, therefore, that only patients with a small
cancer (<1 cm) carrying an exceptionally low risk of
recurrence should be routinely excluded from considera-
tion of treatment with postoperative radioiodine therapy.
Side effects of radioactive iodine. While radio-
iodine is generally well tolerated, a significant percentage
of patients will experience side effects. While most of the
side effects are mild and transient, some are more serious.
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Local side effects are typically transient and occur with
varying incidence: radiation thyroiditis/neck pain (up to
20% of patients), sialadenitis (12%), taste dysfunction
(50%), and nausea (67%) have all been reported [18–
20]. These effects are generally more pronounced with
higher or repeated doses of radioiodine. A potentially
more serious side effect of decreased sperm count has
been reported. While this side effect is common, and
correlates to the dose of radioiodine [21], it is probably
transient and does not result in an increased incidence of
infertility [22]. Perhaps the greatest potential morbidity is
the rare incidence of leukemia after radioiodine therapy.
While this has been reported many times [23–27], the
incidence does not appear to greater than that of the rest
of the population [24,27,28], with the possible exception
of very high-dose radioiodine treatment [23,29].
Outpatient radioiodine. Prior to 1997, an inpatient
treatment setting was required for any patient receiving
>30 mCi of radioiodine. This practice was cumbersome
and required significant resource investment from both
the patient and treating center. In May, 1997, however,
the United States Nuclear Regulatory Committee revised
the regulatory code which allowed patients to be treated
with higher doses (up to 200 mCi) in an outpatient
setting. Unique isolation precautions have arisen from the
regulatory code revisions which protect a patient’s family
and community from excess radiation exposure. These
precautions reduce external exposure to others (limit
proximity to others, limit private travel, limit time at
work, sleeping in a separate bed, avoidance of mouth-
to-mouth contact, using separate dishes, utensils, linens,
and thorough handwashing, etc.). The period of time for
these precautions are short (from 2 to 6 days), and are
relative to the dose administered [30,31].
Radioiodine dosing. Radioiodine dosing regimens
for ablation or therapy are also subject to practice pattern
variation. A typical ablation dose for very the small
amount of remaining thyroid tissue in the thyroid bed
(5% uptake) after thyroidectomy is 30 mCi. Treatment
regimens are more variable, however. Many centers use a
standard fixed dose for all patients, with dose adjustments
made only for site of radioiodine uptake [11,32,33]. In
this method, not less than 100 mCi is given for uptake in
the thyroid bed, not less than 150 mCi for uptake in the
cervical nodes, and not less than 175 mCi for distant
metastases. This is an attractive approach given its sim-
plicity, but more specific alternate dosing regimens are
utilized as well. One common method is a quantitated
dosimetric approach based on the calculated radiation
dose delivered to the cancer cells [34]. By this method,
the calculated dose is given such that after delivery of
200 cGy to the bloodstream, no more than 120 mCi are
retained by 48 hr. This approach can be modified with
a peak-dose limit of 300 mCi per treatment [35].
Another approach that combines elements of the fixed
and adjusted-dose methods is employed at the University
of Michigan. In this method, the fractional retention of a
diagnostic 131I dose is measured at 2 days with a scintil-
lation probe [36]. This simple safeguard allows for
verification that the patient’s fractional retention of 131I is
15%. If so, the patient receives a standard (adult)
treatment dose of 150 mCi (allowing for a relatively low
30 mCi retention at 2 days). If significant differences in
the fractional retention are noted, then dosage adjust-
ments can be made.
Lithium and radioiodine. As mentioned above,
some tumors are de-differentiated and concentrate radio-
iodine poorly, or not at all. In these cases, the use of
lithium may be considered as an adjunct to radioiodine
therapy, based on the fact that lithium reduces the release
of iodine from thyroid tissue. Lithium carbonate is
administered orally (10 mg/kg/day; 400–800 mg daily)
for 7 days prior to radioiodine treatment. The serum
levels should remain between 0.8 and 1.2 mmol/L. In
several small, uncontrolled case series, lithium has been
noted to increase the effective tissue half-life of radio-
iodine in metastatic lesions and in native thyroid tissue
[37,38]. The effect of this phenomenon on recurrence or
mortality has not been studied. It has not been studied on
a larger scale, though, and the routine use of lithium as
an adjunct to radioiodine treatment of WDTC is not
common.
RECURRENT CANCER
Most recurrences of WDTC are within the first several
years after thyroidectomy, and half of those who develop
recurrences do so in the first 5 years [39]. Secondary
screening is carried out every 6–12 months for the first
several years to evaluate for recurrent or metastatic dis-
ease. Modern secondary screening is accomplished with a
combination of physical exam, monitoring of thyroglo-
bulin, and imaging (see Table II). Anti-thyroglobulin
antibodies should be measured at the same time (and each
time) as thyroglobulin. Although TG-Ab may decrease or
disappear over time, if the antibodies are present, the
thyroglobulin level is not valid and cannot be relied upon
to detect recurrent disease. In the presence of TG-Ab,
imaging becomes a more important secondary screening
modality. Although ultrasound assessment of the neck
has been utilized more over recent years, radioiodine
whole-body scanning remains a common method by
which to detect recurrent disease.
In Table I, we describe a practical approach to the
secondary screening of WDTC patients. Of course,
physical exam is necessary for all patients at regular
intervals. The first postoperative thyroglobulin/thyroglo-
bulin antibody (TG/TG-Ab) levels and 131I scan are
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obtained at 6 weeks under conditions of thyroxine with-
drawal. Subsequent TG/TG-Ab levels are unstimulated,
and the trend over time is observed. If there is a concern
over rising levels, a stimulated level can be obtained. This
approach minimizes the duration of hypothyroidism over
the first postoperative year. 131I diagnostic scanning is
performed yearly until negative except in those patients
identified to be in a very-low risk prognostic category.
ALGORITHM FOR
POSTOPERATIVE TREATMENT
Patients with WDTC should be evaluated 4–6 weeks
after total thyroidectomy as described in Table II. These
recommendations assume there is no gross residual
disease in the neck. All patients will receive thyroxine




The radioiodine whole body scan (WBS) detects tissue
with ability to concentrate radioiodine. Some authors
have advocated not obtaining a WBS if the patient has
had an aggressive initial operation with no suggestion of
recurrence by thyroglobulin levels [40]. Nevertheless,
thyroglobulin levels are not 100% sensitive to recurrence
and WBS continues to be widely utilized in early secon-
dary screening. Recurrent cancer is best visualized when
stimulated by TSH. Traditionally this has been accom-
plished in the same manner as for postoperative thyroid
ablation—thyroxine withdrawal for 4–6 weeks, some-
times with the use of T3 to ameliorate hypothyroid
symptoms in the first 4 weeks. The withdrawal period can
be fairly morbid, however, and most patients experience
significant side effects of hypothyroidism: lethargy,
depression, irritability, weight gain, and limitation in
ability to work [41]. Also, there has been concern in small
reports that the prolonged TSH elevation of thyroxine
withdrawal for total-body scanning could be associated
with rapid growth of metastatic tumors, particularly those
in neurologic locations [42]. As such, alternate methods
for thyroid tissue stimulation have been sought. Histori-
cally, bovine and human thyrotropin were used, but more
recently recombinant human TSH (rhTSH; ThyrogenTM)
has become available. Today, rhTSH is produced in the
Chinese Hamster Ovary (CHO) cell line. Traditional
bacterial drug production systems cannot be used as
bacteria lack the cellular mechanisms to glycosylate the
TSH protein [43,44].
ThyrogenTM is approved by the Food and Drug Ad-
ministration for use as an adjunctive diagnostic tool for
radionuclide imaging (and thyroglobulin testing) in the
follow-up of patients with WDTC. The intended goal
when using rhTSH is that residual or recurrent thyroid
tissue cells would receive sufficient stimulation for
effective imaging without having to remove the patient
from their usual thyroxine therapy. Another potential way
that rhTSH could be useful (though not currently ap-
proved by the FDA) is to stimulate recurrent cancer prior
to radioiodine treatment while allowing the patient to
remain on daily thyroxine.
Several studies have compared the rhTSH WBS to
traditional thyroxine-withdrawal WBS. In general, peak
TSH levels are higher in the rhTSH group, but this does
not correlate with the level of uptake on WBS [45]. In one
study, the level of neck radioiodine uptake was lower in
the rhTSH scans when compared to withdrawal scans in
72% of patients. However, the scans were still read as
TABLE II. Evaluation and Treatment After Total Thyroidectomy at 4–6 Weeks
Scan and TG results Action
Thyroid bed positive Radioiodine ablation and post-treatment scana
Metastatic site positive Radioiodine therapy and post-treatment scan
Scan negative, TG low None
Scan negative, TG elevated Consider radioiodine treatmentb
aRadioiodine in this setting is controversial. In a low-risk patient, some clinicians would follow if the
image did not obscure the ability to image the surrounding neck.
bRadioiodine is also controversial in this setting (see text).
TABLE I. Secondary Screening
Screening measure Frequency
Physical exam Every 3–6 months for 2 years, then annually
Thyroglobulin and TG-antibody measurement At 6 weeks, 3 months, 12 months, then annually
131I diagnostic scan Yearly until negative
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equivalent in 89% of cases (in the remaining cases, the
withdrawal scans were superior) [46]. A second study by
Ladenson [47] showed that the rhTSH scans are inferior
29% of the time, concordant to withdrawal scans 66% of
the time, and better in 5% of patients. This study did not
address, however, if the inferior scans were merely de-
creased uptake or if they showed a different stage of
disease. Yet another study showed equivalent scans even
in the setting of decreased radioiodine uptake in the
rhTSH group [45].
Mazzaferri et al. [48] recently published a consensus
statement on the use of serum thyroglobulin levels to
monitor low-risk patients with WDTC. The consensus
panel’s statement represented the collective opinion of 15
senior endocrinologists from around the world. From a
comprehensive literature review, it was determined that
serum thyroglobulin levels were sensitive in the second-
ary screening of patients with WDTC when the serum
levels were 2 mg/ml. The consensus panel additionally
concluded that an rhTSH-stimulated thyroglobulin level
carried an equivalent sensitivity to a traditional thyr-
oglobulin level stimulated by thyroxine withdrawal.
Because of the avoidance of symptoms associated
with thyroxine withdrawal, there has been much interest
in using rhTSH for thyroid tissue stimulation prior to
treatment—that is, not just for stimulation prior to a
diagnostic scan or measurement of serum thyroglobulin
levels. In a single-center uncontrolled case series of
12 patients with late-stage recurrent thyroid cancer,
0.9 mg daily of rhTSH was given subcutaneously for
2 days in order to stimulate uptake of radioiodine at both
imaging and therapeutic doses. All 12 patients showed
correlation between the initial WBS and the post-therapy
WBS. In short-term follow-up, 10 patients had serial
thyroglobulin (TG) levels measured. Four of 10 showed a
decrease in TG, 4 had an increase, and 2 patients had a
stable TG [49]. While rhTSH may have value in the
stimulation of thyroid tissue for diagnostic scanning [50],
caution must be utilized in the extension of this logic to
the use of rhTSH for stimulation prior to radioiodine
therapy. The authors are aware that rhTSH is being used
while on thyroxine for the measurement of stimulated
thyroglobulin levels. We also note that if rhTSH is used
for diagnostic WBS and a lesion is found, it is tempting to
proceed without delay and use rhTSH for stimulation
of uptake prior to treatment (rather than making the
patient withdraw from thyroxine for 6 weeks after the
rhTSH diagnostic WBS). However, we advise caution in
this regard as rhTSH has yet to be established as an
efficacious alternative to traditional thyroxine withdrawal
for radioiodine ablation or therapy. It is currently our
practice to withdraw patients from thyroxine (unless
medically contraindicated) prior to treatment with radio-
iodine.
Thyroglobulin-Positive, WBS-Negative Patients
Another important aspect of secondary screening for
thyroid cancer is the serial measurement of serum thyro-
globulin levels. Elevated TG levels may indicate recur-
rent or metastatic disease [51], particularly in the absence
of thyroglobulin antibodies. Although the intricacies in
this element of surveillance are out of the scope of this
section, there does occasionally arise a clinical dilemma
in which the thyroglobulin level is elevated (suggesting
recurrence), but the radioiodine WBS is negative as well
as all anatomic imaging studies such as ultrasound and
CT scan. Clark et al. [52] have commented on several
possible reasons behind this difficult situation. Of course,
TG levels should always be rechecked in this scenario as
lab error may occur. However, the elevated TG may re-
present a true recurrence, but of a tumor that is too diffuse
and small for detection. Additionally, the recurrent cancer
may be shielded from positive imaging by remaining
normal thyroid tissue (not an issue if the original
operation was a near-total or total thyroidectomy). Final-
ly, the uptake of 131I may be blocked by high levels of
non-radioactive iodine from excess (or non-restricted)
dietary intake. This can be excluded by checking a
urinary iodine level, which should be less than 200 mg/
day/g creatinine. Some tumors may also dedifferentiate
in a manner such that they are able to secrete thyro-
globulin but have lost the ability to trap iodine. If the
non-diagnostic imaging is not due to any of the alter-
able causes above, the clinician is left not knowing if
the patient may have a recurrence that would necessitate
radioiodine therapy. Five studies have addressed this
issue in a total of 79 patients who had normal diagnostic
WBS and an elevated TG levels [3]. All were treated and
in 66/79 patients the positive post-therapy scan was
positive. That is, the smaller diagnostic dose of radio-
iodine did not visualize the recurrent or metastatic
disease. Therapeutic doses of radioiodine have been
advocated in the setting of scan-negative, TG positive
patients [53], but this has yet to be established as a safe
and efficacious practice. Even if some of the TG levels
decrease, Fatourechi [54] has documented a lack of tumor
response in these patients who do get treatment after
negative WBS scans. It remains to be seen if there will be
an impact on tumor recurrence or cause-specific survival.
An alternative would be to use higher doses of radio-
iodine for imaging, but there are concerns that the initial
diagnostic dose would stun the thyroid tissue and
ultimately decrease the level of therapeutic radioiodine
uptake.
REDIFFERENTIATION THERAPY
Adjunctive treatment of WDTC is dependent on the
uptake and concentration of radioiodine by cancerous
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thyroid tissue. Problematically, it has been reported that
as many as 30% of advanced WDTC will eventually de-
differentiate [55], and a portion of these cancers will
lose the ability to concentrate radioiodine. This may be
due to decreased expression of the human sodium iodide
symporter (hNIS). Both in vivo and in vitro research has
shown that follicular cancer cell lines have greater iodine
uptake when stably transfected with hNIS [56]. Applica-
tion of these gene therapy techniques to human subjects is
not a current reality, but remains an exciting area of re-
search [57]. Certain therapies have been used in humans
in effort to ‘‘redifferentiate’’ thyroid cancer cells such
that they would regain the ability to concentrate radio-
iodine. In early pilot studies, retinoic acid has been shown
to increase radioiodine uptake and decrease thyroglobulin
levels in advanced thyroid carcinomas [58], and further
studies hold promise for the treatment of de-differen-
tiated tumors.
NEW HORIZONS IN THE TREATMENT OF
THYROID CANCER
There are no significantly effective medical therapies to
offer patients with radioiodine-resistant thyroid cancers.
In addition to the redifferentiation therapies mentioned
above, the past two decades of research into the
molecular biology and genetics of thyroid cancer have
identified potential targets for alternate therapies. In a
recent comprehensive review by Braga-Basaria and
Ringel [59], the newest advances in thyroid cancer
treatment were thoroughly summarized. Clinical trials
have been established for a variety of drugs with wide-
ranging targets and molecular mechanisms of actions,
including drugs that target: intracellular signaling mole-
cules (ras and raf inhibition), receptor tyrosine kinases
(anti-VEGF, anti-EGFR, anti Her2/neu, and VEGF/EGF
receptor inhibitors), angiogenesis (thalidomide, com-
bretastatins), apoptotic pathways (TRAIL; TNF-related
apoptosis-inducing ligand), and rapamycin’s effect on the
mTOR gene (mammalian target of rapamycin). These and
multiple other new drug therapies are summarized in this
review; and a re-emphasis is made that all patients with
radioiodine-resistant tumors should be considered as
candidates for clinical trials.
CONCLUSION
The lack of prospective, randomized data poses
difficulty when deciding how to best manage WDTC.
Nevertheless, extensive retrospective experience and
rational use of treatment including 131I has allowed for
success in the treatment of papillary and follicular thyroid
cancers. Disease-specific mortality remains exceptionally
low for small cancers in low-risk patients, while larger
tumors and recurrences can usually be effectively treated
with surgery and radioiodine. The mainstay of treatment
for WDTC greater than 1 cm remains near-total or total
thyroidectomy with postoperative 131I, then subsequent
surveillance with thyroglobulin levels, physical exam,
and selected imaging. Exciting new gene therapy and
tumor redifferentiation research holds promise in dis-
covering new methods to improve radioiodine therapy for
patients with advanced disease.
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